SCHEMBL6982596

SCHEMBL6982596

CC(C)CC(NC(=O)OC(C)(C)C)C(=O)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
MAPK1 P28482 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
HRH2 P25021 2/20 0.51
HRH1 P35367 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MC4R P32245 2/20 0.50
CCR1 P32246 4/20 0.48
GAA P10253 1/20 0.47
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981597 0.89 MAPK1 (0.52) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL6982783 0.89 MAPK1 (0.61) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL6976074 0.89 MAPK1 (0.52) SMN1; SMN2HTTNPSR1MAPK1ALDH1A1
SCHEMBL6985297 0.88 ALDH1A1 (0.65) SMN1; SMN2HTTMAPK1ALDH1A1LMNA
SCHEMBL6980930 0.85 MAPK1 (0.59) NPSR1MAPK1ALDH1A1LMNAHRH2
SCHEMBL4510471 0.82 MC4R (0.56) SMN1; SMN2HTTNPSR1MAPK1HRH2
SCHEMBL6986093 0.80 MAPK1 (0.56) SMN1; SMN2HTTMAPK1ALDH1A1LMNA
SCHEMBL1706172 0.79 MAPK1 (0.55) NPSR1MAPK1ALDH1A1LMNAHRH2
SCHEMBL12535753 0.79 MAPK1 (0.55) NPSR1MAPK1ALDH1A1LMNAHRH2
SCHEMBL1706174 0.79 MAPK1 (0.55) NPSR1MAPK1ALDH1A1LMNAHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed